Kornimate/medical-research-clean huggingface dataset:
evaluation of the onset and duration of action of bepotastine besilate ophthalmic solution in acute allergic conjunctivitis

Conditions: Conjunctivitis, Allergic

Summary: the purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis


Eligibility criteria:
inclusion criteria: * at least 10 years of age \& either sex, any race * willing and able to follow all instructions and attend all study visits * positive history of ocular allergies exclusion criteria: * have planned surgery during trial period * female currently pregnant, planning a pregnancy, or lactating
post-covid-19 monitoring in routine health insurance data with focus on autoimmune diseases (pointed-ad)

Conditions: Virus Diseases

Summary: the sars-cov-2 (severe acute respiratory syndrome coronavirus type 2) infection was in 2020 responsible for new disease related chronic conditions which have been referred to as post-covid. to date it is still unknown how common this condition is and how it might effect the working of the immune system. the aim of the study is therefore to monitor the onset of autoimmune diseases in a large observational study consisting of german health insurance data.

sars-cov-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. the sars-cov-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as post-covid. to understand how the virus might effect the working of the immune system a large observational study of health insurance data from germany was set up. the exposed patients were identified by a diagnosis indicating a confirmed laboratory test for covid-19. the basic question concerns the burden of the post-covid condition. the study investigate which autoimmune diseases or groups of autoimmune diseases are more common in humans after the exposure to the virus compared to a matched unexposed cohort. further will this be investigated in subgroups of the population.

Eligibility criteria:
inclusion criteria: * at least one outpatient or inpatient diagnosis of covid-19 with laboratory detection of the virus (icd-10: u07.1!) in the year 2020 * continuously insured with the respective health insurance between 2019-01-01/birth and 2021-06-30/death exclusion criteria: * only an outpatient or inpatient diagnosis of covid-19 without laboratory detection of the virus( icd-10:u07.2!) till 30th of june 2021 * at least one outpatient or inpatient diagnosis of covid-19 with laboratory detection of the virus (icd-10: u07.1!) in the first half of the year 2021
pilot study to determine the optimal technique for measurement of ankle blood pressures

Conditions: Peripheral Arterial Disease

Summary: peripheral arterial disease (pad) is a highly prevalent medical condition. patients with pad are usually diagnosed on the basis of the ankle-brachial index. the ankle-brachial index is the ratio of ankle pressure to arm pressure based on measurement of blood pressures in the arms and legs using a doppler device. the need for dedicated equipment and trained personnel, along with the time required to perform the test, have been identified as barriers to widespread implementation of ankle-brachial index screening. the use of automated oscillometric devices for blood pressure measurement and determination of the ankle-brachial index has been applied with variable success. it will be beneficial to investigate a reliable oscillometric-based procedure that can accurately measure leg pressures for the ankle-brachial index across the entire spectrum of pad severity. the purpose of this study is to determine the optimal oscillometric-based technique for estimation of doppler-derived systolic arm and ankle blood pressures for calculation of the ankle-brachial index in patients with and without pad. subjects with suspected arterial disease in the non-invasive lab will be enrolled. arm, ankle, and toe pressure measurements will be made in the supine position using doppler, oscillometric methods, and photoplethysmographic sensor. arm and ankle pressures from a subset of subjects will be obtained in both seated and supine positions. the ankle-brachial index and toe-brachial index will be calculated.


Eligibility criteria:
inclusion criteria: * patient at least 50 years of age * ambulatory outpatient * referred to non-invasive vascular laboratory for evaluation of suspected arterial disease. exclusion criteria: * unable to give informed consent * unable to lie supine for at least 15 minutes
a-link: improving outcomes in autoimmune liver disease

Conditions: Autoimmune Hepatitis; Primary Sclerosing Cholangitis

Summary: the autoimmune liver disease network for kids (a-link) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (aild). this study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. pediatric autoimmune hepatitis (aih) and primary sclerosing cholangitis (psc), represent a spectrum of aild which present unique diagnostic and therapeutic challenges.a lack of accepted guidelines for disease monitoring or symptom management results in wide treatment variation with liver transplants indicated in refractory, progressive disease. the aims of a-link are to: 1.) create a learning health network focused on patient-centered outcomes research characterized by transparent sharing among centers, common priorities, and feasible plans for implementing new practices; 2) shift from traditional investigator-driven study to a patient and family-centered approach, and 3.) improve clinical outcomes and quality of life for pediatric aild patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of autoimmune hepatitis (aih) * clinical diagnosis of primary sclerosing cholangitis (psc) * clinical diagnosis of autoimmune sclerosing cholangitis (asc) exclusion criteria: • history of liver transplant

Keywords: pediatrics autoimmune hepatitis primary sclerosing cholangitis autoimmune sclerosing cholangitis chronic liver disease end-stage liver disease clinical registry research registry quality improvement outcomes research comparative effectiveness research patient reported outcomes health services research
balanced solutions and plasma electrolytes

Conditions: Critical Illness; Acidosis, Metabolic

Summary: the administration of intravenous fluids is ubiquitous in the care of the critically ill. commonly available isotonic crystalloid solutions contain a broad spectrum electrolyte compositions including a range chloride concentrations. recent prospective, randomized trials have shown improved patient outcomes with the use of balanced crystalloids compared to saline. there have not been large randomized studies comparing acetate buffered balanced crystalloids to non-acetate buffered balanced crystalloids in the critically ill. base will be a pilot study for a large, cluster-randomized, multiple-crossover trial enrolling critically ill patients from the medical icu at vanderbilt university from june 2018 until january 2019. the primary endpoint will be plasma bicarbonate concentration between intensive care unit admission and hospital discharge.

base is a pilot, cluster-randomized, multiple-crossover trial of lactated ringer's versus normosol-r ph 7.4 with regard to plasma bicarbonate concentration between intensive care unit admission and hospital discharge among all patients admitted to the medical intensive care unit. between june 2018 and january 2019, all patients admitted to the medical intensive care unit at vanderbilt university medical center who are 18 years or older will be enrolled. the study will occur in one-month blocks. the medical intensive care unit (micu) will be randomized to an initial fluid group (lactated ringer's or normosol). the assigned fluid will be used exclusively for all patients receiving isotonic crystalloid for the duration of the month-long block (except in the presence of pre-specified contraindications). the assigned study fluid will switch at the end of each month-long block such that half of hte months are assigned to lactated ringer's and half of the months are assigned to normosol-r ph 7.4. it is anticipated that around 2,000 patients will be enrolled from the medical icu during the study period. the primary outcome analysis will be an intention-to-treat comparison of the primary outcome of bicarbonate concentration (mmol/l) between enrollment and 7 days after enrollment between the lactated ringer's and normosol-r groups using generalized estimating equations with a random effect for study period and accounting for repeated measures.

Eligibility criteria:
inclusion criteria: * patients admitted to the medical icu during the study period (enrolled patients who are discharged from the hospital are eligible again if they are readmitted to the medical icu during the study period) exclusion criteria: * age \< 18 years old * prisoners

Keywords: balanced crystalloid crystalloid isotonic acetate non-acetate lactated ringer's normosol
washed versus standard blood cell transfusions in pediatric open heart surgery

Conditions: Congenital Heart Disease

Summary: background: children having open heart surgery to repair congenital heart defects demonstrate a large inflammatory response to the heart-lung machine and to surgery itself. in general, the more intense their inflammatory response, the more critically ill they are following surgery. these children routinely require large numbers of blood transfusions during and following surgery as part of their medical management that adds to their heightened inflammatory state. whether additional steps to "wash" blood products and remove the substances contributing to post-transfusion inflammation will limit this response, and improve the health of children following open heart surgery, remains to be studied. aims: to compare the inflammatory response in children having open heart surgery who receive washed versus unwashed blood transfusions. methods: we will randomly assign children having open heart surgery to one of two groups: group 1 will receive blood transfusions per the current standard of care, group 2 will receive blood transfusions that have been washed in addition to the current standard of care. we will then use blood tests to measure the inflammatory response in children of each group. we will compare the results to determine whether washing blood transfusions decreases inflammation and post-operative complications following open heart surgery. conclusion: we believe that washing blood transfusions given to children following open heart surgery will decrease their inflammatory response and improve their overall health.


Eligibility criteria:
inclusion criteria: 1. age \< 18 years 2. surgical repair at urmc by the pediatric cardiac surgical team 3. informed consent signed by the parent or legal guardian, and if applicable, assent obtained from the subject. exclusion criteria: 1. age ≥18 years 2. inability to provide consent/assent; 3) subjects having "emergent" surgical procedures. subjects with chronic inflammatory or autoimmune disorders will not be excluded

Keywords: pediatrics congenital heart disease
fascial manipulation on the treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the trial aims to evaluate the effectiveness of fascial manipulation on pain reduction, functional recovery and nerve conduction of patients with carpal tunnel syndrome (cts). visual analogue scale (vas), disabilities of the arm, shoulder and hand scale (dash), boston carpal tunnel syndrome questionnaire (bctq) and electroneuromyography were assessed. the study is blind for the patient and the raters.

this is a prospective, randomized, placebo controlled, rater blind trial to evaluate the effectiveness of fascial manipulation as a therapy for cts. fascial manipulation is an intense friction performed by the elbows or the distal extremities of the interphalangeal articulation of the index finger for some minutes as to promote hyperemia to restore the collagen fibers ability to slide against each other. the friction lasts from 2 to 4 minutes. in this trial, 14 patients were randomized in two groups: the intervention group received fascial manipulation for cts and the other group, received fascial manipulation on spots not related to cts. this last group was the placebo control group. the treatment was performed once a week for 5 weeks consecutively and the follow up visits for the assessments were performed 10 days and 3 months after the end of the treatment.

Eligibility criteria:
inclusion criteria: * cts degrees ia, ib and ii diagnosis according to clinical evaluation and electroneuromyography; * wrist and finger paresthesia for more than 3 months prior to screening visit; * moderate to intense pain: vas\>4. * ability to understand and respond to the questionnaires used in the trial; * ability to understand the informed consent form; * sign the informed consent form. exclusion criteria: * psychiatric disorders; * fibromyalgia; * rheumatologic diseases; * other conditions related to cts, as renal failure, diabetes, acromegaly, hyperthyroidism, multiple myeloma; * history of neoplasia; * history of surgery at carpal tunnel; * history of use of illegal drugs; * history of chronic use of corticosteroids; * corticosteroid infiltration one month prior to inclusion in the trial.

Keywords: fascial manipulation carpal tunnel syndrome
internet and social media use in dermatology patients

Conditions: Dermatologic Diseases

Summary: this study is to assess internet and social media use in dermatology patients

the internet and social media bear potential in terms of heath care consumer education, prevention of diseases and dissemination of evidence-based information. the use of the internet and social media platforms both by dermatologists and patients is rapidly evolving. in order to improve the presence and visibility of dermatology-related evidence-based informations on the internet and in social media, the use and behavior of dermatology patients in this context is studied in more detail.

Eligibility criteria:
inclusion criteria: * patients treated at the department of dermatology of university hospital basel exclusion criteria: * insufficient knowledge of german language

Keywords: social media use online medical services internet use
efficacy and safety study on menatetrenone in the treatment of postmenopausal osteoporosis women

Conditions: Postmenopausal Osteoporosis

Summary: to determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.


Eligibility criteria:
inclusion criteria : * postmenopausal women with menopause duration more than 5 years and with age between 45-75 years old (menopausal age ≥40), or if hysterectomy operated before natural menopause, the age of women between 60-75 years old. * subject with bmd (l2-4 or neck of femur) being more than 2 standard deviation (sd) below the young female adult mean (according to the standard of each center) * bmi between 18 kg/m2-30 kg/m2. * the anatomic structure of lumbar spine must be available for dual-energy x-ray absorptiometry (dexa) examination, patient with serious scoliosis, bone trauma or sequela after orthopedics surgery, which makes bmd measurement difficult, should be excluded * subject who have given informed consent prior to participation in the trial and who undertake to comply with the protocol. exclusion criteria * subject with conditions that are considered to effect osteoporosis, such as clear definite diabetes mellitus, rheumatoid arthritis, rheumatoid arthritis, hyperparathyroidism or other bone metabolic diseases. * subjects who have received treatment with active-type vitamin d3 preparation, other vitamin d preparations (\>1000iu per day）, calcitonin, corticosteroid hormone, androgen, estrogen, other hormone, vitamin k preparation, in the 3 months prior to inanition of this study; subjects who have received treatment with bisphosphonate preparation or sodium fluoride in the 1 year prior to inanition of this study; subjects who have received treatment with selective estrogen receptor modulator (serm) in the 6 months prior to inanition of this study * concurrent serious renal disease, hepatic disease, uncontrolled hypertension （≥150/100mmhg）, symptomatic ischemic heart disease, cerebral infarction or arteriosclerosis obliterans. * cancer history within 5 years. * subjects who take antacid containing aluminum in the preparation, warfarin or thrombolytic agents. * subject with any known abnormality in laboratory tests, which is deemed to be clinically significant by the investigator, which include: * serum alkaline phosphatace (alp) \> upper normal limit 10% (calculated according to the range of normal values of each center); * glutamic oxalacetic transaminase (ast)/ glutamic pyruvic transaminase (alt) \> upper normal limit 50％(calculated according to the range of normal values of each center); * serum creatinine \>1.5mg/dl (133μmol/l); * blood-fasting sugar ≥ 7mmol/l (126mg/l) * inability of subject to return for scheduled visits or to comply with any other aspect of the protocol. * subject who, in the opinion of the investigator, are poor medical candidates or pose any other risk for therapy with an investigational drug.

Keywords: postmenopausal osteoporosis
clinical study of bns003 on swelling in legs due to venous reflux

Conditions: Venous Insufficiency

Summary: to investigate the efficacy and safety of bns003 on subjective symptoms such as sensation of heaviness/tiredness(dullness), tension, tingling, pain, fever or itching associated with swelling of calf and ankle due to disorder of leg venous reflux.


Eligibility criteria:
inclusion criteria: * manifestation of swelling falling into class 1 according to porter's classification * with more than 2 symptoms of "sensation of heaviness/tiredness (dullness)," "tension," "tingling," "pain," "fever" or "itching" and a total score of \>=3 for severity by symptoms * persons aged 20 years or older at the time of obtaining their informed consent and available for hospital visits. both genders are acceptable * persons who have consented to participating in the study in written form with good understanding of the objective of the study, the methods, and notices for the study period exclusion criteria: * persons with edema not due to venous diseases of the legs (e.g., lymphedema, latent cardiac or renal insufficiency, etc.) * persons with peripheral arterial diseases * persons with acute phlebitis, venous ulcer, congenital vascular anomaly, or behcet's syndrome * persons with "moderate" or "severe" renal, hepatic, cardiac or haematological disorder, or with a history of such disorder (grade 3 or 4 in common toxicity criteria (ctc)) * persons with diabetes mellitus (excluding those curable with dietary therapy), neuropathy, hyper-or hypocalcemia, or malignant tumors * persons with drug or alcohol abuse * persons with immobility * persons with pulmonary embolism * persons with hypersensitivity to drugs (particularly to the ingredients contained in the investigational drug) * persons with clinical indication of requiring venous treatment such as physical application (use of elastic bandage and compression stockings) and phlebectomy (vein stripping surgery to remove vein affected with varicosis and valve insufficiency) * persons who received venous sclerosing therapy within the last 4 weeks before starting this study * persons who constantly use theophylline preparations, diuretics, cardiac glycosides * persons who had changed to or initiated post-menopausal hormone replacement therapy within the last 2 months before starting this study * persons unable to suspend the frequent use and exceeded dosage/administration of laxatives (more than 6 times) during the study period * persons planned to undergo a surgery requiring systemic anesthesia during the study period * women in pregnancy or nursing, or those who wish for a pregnancy during the study period * persons who participated in another study within the last 3 months before starting this study, or who plan to participate in another study during the study period * persons who were considered to be ineligible to be a subject for the trial by the investigator or sub-investigators
infant respiratory interface and accessories evaluation study

Conditions: Respiratory Distress Syndrome, Newborn

Summary: determine the usability of an interface and its accessories to provide non-invasive respiratory therapy to neonates and infants.


Eligibility criteria:
inclusion criteria: * spontaneously breathing infants who require non-invasive respiratory support * parent(s)/guardian(s) at least 18 years of age exclusion criteria: * parent(s)/guardian(s) unable to give written informed consent * neonate or infant not requiring non-invasive support * suspected or confirmed abnormalities or trauma to the skull or airway
improving the criteria for selecting patients for primary prevention of sudden cardiac death by arrhythmic risk stratification

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: a number of large randomized studies have demonstrated the importance of left ventricle ejection fraction (lv ef) for ventrucular tachyarhrythmia's (vt) prediction. the use of this indicator as the sole predictor of high arrhythmic risk requiring icd implantation is enshrined in the current clinical recommendations. at the same time, many experts consider lv ef as too generalized indicator, which can be an integral indicator of total cardiovascular mortality, but lacks specificity in determining the risk of vt. it is known that only about 20% of patients with icd implanted for primary prevention of sudden cardiac death (scd) receive appropriate life-saving therapy. purpose of the study: to develop additional criteria for selection of patients with heart failure for implantation of cardioverter-defibrillator for the purpose of primary scd prevention on the basis of stratification of the risk of occurrence of stable ventricular tachyarrhythmias.


Eligibility criteria:
inclusion criteria: * lv ef ≤ 35% inspite of optimal drug therapy of heart failure (3 months and longer) * nyha ii-iv * favorable prediction of survival for 1 year or more exclusion criteria: * secondary scd prevention * indications for open heart surgery * hypertrophic cardiomyopathy * arrhythmogenic right ventricular dysplasia * genetic channelopathies

Keywords: sudden cardiac death heart failure primary prevention risk stratification